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Abstract
Aim: Serum osteocalcin was shown in a previous study
on first trimester pregnant women to correlate with bone
density and to distinguish between fast and slow bone
losers. The objective of the present study is to examine
whether serum osteocalcin is related to vitamin D recep-
tor (VDR) BsmI polymorphism in pregnant women.
Study design: We determined osteocalcin serum levels
and VDR BsmI genotype in 97 healthy first trimester
pregnant women consecutively recruited during six
months.
Results: BB (21%), Bb (38%) and bb (41%) genotypes
showed similar osteocalcin serum levels. However, in pri-
migravidas (ns38) the BB genotype was significantly
associated with higher mean osteocalcin level (9.67
ng/mL) than the Bb (8.07 ng/mL) and the bb genotype
(8.14 ng/mL), respectively (P-0.05). The VDR genotype
was the only independent parameter to correlate with
serum osteocalcin (P-0.05).
Conclusion: Only primigravidas show in the first trimes-
ter a relation between the bone formation parameter
serum osteocalcin and the VDR genotype BB which indi-
cates a higher risk of fractures. For further clinical appli-
cations serum osteocalcin and VDR genotype should be
tested on a cohort of primigravidas including measure-
ments of bone density.
Keywords: Bone metabolism; osteocalcin; osteoporosis;
VDR polymorphism.
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Introduction
Osteoporosis is a multifactorial disease that involves a
reduction in bone mineral density (BMD). Since osteo-
porosis is a late-onset disease, the development of early
diagnostic modalities and preventive measures are
urgently required. Environmental and genetic factors are
interacting in establishing the individual osteoporotic risk.
Among multiple candidate genes in relation to BMD,
such as estrogen receptor and collagen I gene polymor-
phisms, in addition to the TGFb1-regulating genes w4x,
the vitamin D receptor (VDR) gene at the 3’ end allele
was the first described w15x. BsmI polymorphism is one
of the four VDR gene polymorphisms known to date,
which are differently related to BMD. Age, gender, race
and diet play key roles. Therefore, crucial relations of
VDR polymorphism and BMD exist from studies with dif-
ferent populations.
Post-menopausal women are the major at-risk sub-
group for osteoporosis w8x. Moreover, pregnancy has dif-
ferent impact on bone mineral metabolism and density
w6, 9x. In a meta-analysis, mean loss of BMD was con-
sidered as up to 5% w9x. However, it could be shown that
women with many children had similar or higher BMD
than their nulliparous controls. Parity obviously does not
increase the risk of BMD loss or other factors may be
determinants such as bone metabolism in pregnancy. We
recently demonstrated that trabecular bone density in
pregnancy varied between slow and fast bone losers dur-
ing the first trimester w19x. Thereby, the only independent
biochemical parameter significantly associated with the
rate of bone loss was serum osteocalcin which could
distinguish slow from fast losers. BsmI polymorphism
occurs in 18% in Caucasian population with the BB
genotype w4, 8x. The first study with sufficient statistical
power included white nurses in a health cohort and dem-
onstrated a two-fold increase in the risk of hip fractures
among BB genotypes in association with older age and
lower calcium intake w5x.
Osteocalcin gene expression is regulated by the VDR
gene w14x. It was the goal of the present study to pro-
spectively test if higher osteocalcin levels indicating fast
bone losers are also associated with the BB genotype.
Bone chemistry in our previous study was not consistent
between first and third trimester demonstrating pregnan-
cy associated adaptations. From these results we sug-
gested that bone metabolism may change within
pregnancy and we hypothesized for our present study
that gravidity i.e., the first pregnancy, could also play an
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Table 1 Maternal characterizing data at blood sampling
(ns97).
Age (years) 28.4"0.5
Height (m) 1.64"0.01
Actual weight (kg) 61.8"0.9
BMI (kg/m2) 22.86"0.3
Actual gestational age (weeks) 12.4"0.1
Gravidity )1 (yes; no) 59; 38
Nulliparity (yes; no) 50; 47
Caucasian (yes; no) 74; 23
Asian (yes; no) 12; 85
African (yes; no) 9; 88
Oriental (yes; no) 2; 95
Continuous values: mean"SE.
Numeric values: n.
important role. Our second endpoint was, therefore, to
compare the relationship between osteocalcin and VDR
genotype in primi- and multigravidas.
Material and methods
Subjects
Following approval of the local ethical committee and with their
informed consent, we consecutively recruited healthy first tri-
mester pregnant primigravidas and multigravidas during routine
control in the Obstetric Clinic of Zurich University Hospital,
Switzerland over a 6-month period. Inclusion criteria to this
prospective study were uncomplicated singleton pregnancies
between 10.0 and 16.0 weeks of gestation by ultrasound. Exclu-
sion criteria were multiple gestation, age -18 and)40.0 years,
BMI )30.0 at inclusion, preexisting maternal diseases such as
diabetes and hypothyroidism, and drug abuse (incl. tobacco).
Patient data were obtained from the patient notes.
Venous blood (3 mL) was collected between 8:00 and
10:00 am into EDTA containing tubes which were stored at
–808C until analysis of VDR; 10 mL were collected into native
tubes kept immediately at 48C and centrifuged 10 min after
venepuncture at 48C, the serum was immediately transferred
into 800 mL aliquots for storage at –208C until analysis of
osteocalcin.
Laboratory methods
Vitamin D receptor (VDR) genotype Peripheral blood collect-
ed in EDTA vacutainers was frozen (whole blood) and stored at
–808C until extraction. Genomic DNA was extracted from whole
blood by MagNA pure compact instrument using the MPC
nucleic acid isolation kit I according to the manufacturer’s
instructions (Roche Applied Science, Germany) and quantified
by UV absorption at 260 nm. Genotyping of the single nucleotide
polymorphism BsmI (A)G in intron 8) was performed by PCR
amplification of a region of the VDR gene spanning the BsmI-
site, followed by restriction endonuclease digestion. After diges-
tion DNA fragments were separated on ethidium-bromide
stained 2% agarose gels and VDR genotype was determined by
UV illumination, identifying the wild type allele or the mutated
allele, respectively. Homozygous presence of the wild type site
(bb) resulted in two fragments of 195 base pairs (bp) and 164 bp,
while homozygous absence of the restriction site (mutated site
BB) resulted in a single fragment of 359 bp. A heterozygous
genotype (Bb) was identified by DNA fragments of 359 bp,
195 bp and 164 bp.
Osteocalcin Osteocalcin in serum was measured by enzyme
immunoassay (EIA; osteocalcin intact human) from Metra
(www.teco-medical.ch) (intra-assay variation -6%, inter-assay
variation -10%; detection limit 0.45 ng/mL). Samples were
assayed in duplicates (the mean value was used) according to
the manufacturer’s protocol. In a precedent setting six different
samples were analyzed by both, the EIA and the previously used
IRMA method w19x which is not anymore commercially available
and the values were compared by using the Bland-Altmann-Plot
w2x. It could be shown that IRMA values were 2.14 lower than
EIA values (mean ratio 2.14 with limits of agreement between
2.00 and 2.27).
Endpoints
The primary endpoint was the relationship between VDR geno-
type and serum osteocalcin in the typical population of our
clinic. The second endpoint was the comparison of such a rela-
tionship between primi- and multigravidas.
Statistical analysis
Statistical analysis was performed using SPSS 10 for Windows.
Data are expressed as mean"SE. Differences between groups
were examined using the Mann-Whitney U-test as well as the
unpaired two-tailed t-tests of log values. Group interactions with
other parameters were tested using analysis of variance (ANO-
VA). Correlations between variables were tested by logistic and
simple regression. A P-0.05 was considered significant in all
tests. The sample size of 20 (in each group) was adequate
(power )80%, as0.05) for detecting a difference )20%
between the median of osteocalcin serum concentration in dif-
ferent VDR genotypes.
Results
Subjects
After the exclusion of three falsely recruited women who
did not meet the inclusion criteria (one with a BMI of
31.0 kg/m2 and two with multiple pregnancy), the popu-
lation numbered ns97 first trimester pregnant women
with a mean age of 28.4 years and an actual BMI of
22.9 kg/m2. The majority of women were Caucasians
(76.3%) (Table 1). Data for the outcome of pregnancy
could be recorded in ns94; one woman had an abortion
in the 18th week, and two women delivered out of the
country. The outcome of these 94 women was uncom-
plicated in 78.7%. Four women had gestational diabetes
without further problems and two had mild preeclampsia
(edema; proteinuria F5 g/24 h, systolic/diastolic blood
pressure )140F160/)90F110 mm Hg). Three women
had other complications (streptococcus B infection ns1,
toxoplasmosis infection ns1, fetal malformation ns1).
The mean gestational age at delivery was 39.3 weeks;
six women delivered between 35.0 and 37.0 weeks.
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Figure 1 (A) Mean"SE osteocalcin serum concentration
(ng/mL) in VDR BsmI genotypes showing significantly higher
levels in primigravidas with the BB allele (ns6) than with the
Bb (ns17) or bb (ns15) alleles or than in multigravidas (BB,
ns14; Bb, ns20; bb, ns25), *P-0.05 (Mann-Whitney U-test
and unpaired t-test of log values, respectively). (B) Mean"SE
osteocalcin serum concentration (ng/mL) in VDR BsmI geno-
types showing no significantly different levels in nulliparas with
the BB allele (ns9) than with the Bb (ns23) or bb (ns19) alleles
or than in multiparas (BB, ns11; Bb, ns14; bb, ns21).
Table 2 VDR BsmI genotype and corresponding serum osteocalcin (ns97).
Genotype Race n (%) Osteocalcin (ng/mL)
EIA raw data To IRMA transposed data
All All 97 (100) 8.30"0.26 (4.01–16.65) 3.81"0.13 (1.72–7.87)
BB All 20 (20.6) 8.42"0.34 (5.56–11.48) 3.87"0.17 (2.48–5.35)
Caucasian 17 8.57"0.36 (6.54–11.48) 3.94"0.18 (2.95–5.35)
Bb All 37 (38.1) 8.33"0.50 (4.19–16.65) 3.82"0.24 (1.81–7.87)
Caucasian 28 8.43"0.55 (4.89–16.63) 3.87"0.27 (2.14–7.86)
bb All 40 (41.3) 8.20"0.40 (4.01–14.97) 3.76"0.19 (1.72–7.05)
Caucasian 29 8.49"0.48 (4.01–14.97) 3.90"0.23 (1.72–7.05)
Continuous values: mean"SE (range).
Numeric-values: n.
Vitamin D receptor (VDR) genotype and serum
osteocalcin
While bb was the most prevalent VDR BsmI genotype
(41.3%), BB was the least prevalent (20.6%) in this group
of women (ns97). In our Caucasian women (ns74) the
distribution was 23%, 37.8% and 39.2%, in Asian
women (ns12) 16.7%, 33.3% and 50%, and in African
women (ns9) 11.1%, 33.3% and 55.6% for BB, Bb and
bb genotypes, respectively. The two Oriental women had
both the Bb genotype. The BB homozygotes were asso-
ciated with higher serum osteocalcin levels compared
with the Bb heterozygotes or the bb homozygotes (Table
2). In primigravidas (ns38) the difference was statistically
significant (9.67 ng/mL in BB vs. 8.07 ng/mL in Bb and
8.14 ng/mL in bb genotypes; P-0.05) (Figure 1A). No
significant differences were found between nulliparas and
multiparas (Figure 1B), nor between women with and
without pregnancy complications (data not shown). There
were also no differences between the subgroup of Cau-
casians and the whole collective (Table 2). Osteocalcin
values in primigravidas ranged between 6.06 and
16.63 ng/mL suggesting a 2.14-fold higher level than in
our previous study determined by the IRMA method w19x.
The ROC curve showed that an osteocalcin concentra-
tion of 7.19 ng/mL in primigravidas discriminated be-
tween fast and slow losers with 53.1% sensitivity and
100% specificity (Figure 2). The VDR genotype was the
only independent variable correlating with osteocalcin in
fast and slow losers in a logistic regression model
(P-0.05) including age and BMI in primigravidas
(Table 3).
Discussion
To our knowledge, no previous study exists demonstrat-
ing higher osteocalcin levels in pregnancy and its relation
to the VDR genotype BB.
The new finding in our study is that only primigravidas
show the association between osteocalcin serum con-
centrations and VDR based on a number of robust find-
ings. Blood sampling for osteocalcin was standardized
(time of blood sampling, handling and storage of serum).
The concentration which discriminates between fast
and slow bone loser was 7.19 ng/mL corresponding to
3.36 ng/mL which is similar to that found in our previous
study (3.67 ng/mL). We could also show that no other
independent variables exist other than VDR genotype
that correlates with osteocalcin levels. The distribution of
VDR genotype at the gene locus BsmI in our Caucasians
was similar (23%) to that in previously published studies
(18–20%) w4, 8x. However, in our Asians (ns12), the BB
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Figure 2 Serum osteocalcin (OC) ROC curve differentiating fast
from slow bone losers in primigravidae (ns38).
Table 3 Logistic regression model using age, body mass index
(BMI) and vitamin D receptor (VDR) BsmI genotype (independent
variables) in 38 primigravidas with osteocalcin -/G3.36 ng/mL
(dependent variable).
P-value OR* 95% confidence
interval
Age 0.518 0.949 0.808–1.113
BMI 0.222 0.852 0.658–1.102
VDR BsmI genotype** 0.038 0.066 0.005–0.860
*Adjusted. **BB vs. Bb or bb.
genotype occurred more frequent (16%) than in other
studies with Asians (1–2%) w4, 10, 18, 20x.
There are also some limitations in our study. For exam-
ple, since higher osteocalcin levels correlated with the
BB genotype, we had only a small number of primigra-
vidas with this genotype (all, ns38; BB genotype, ns6).
We also did not account the consumption of calcium
because in our previous study w19x we could demon-
strate that bone density was independent from calcium
intake.
The fact that a relationship exists between higher
osteocalcin serum levels and VDR BB genotype in pri-
migravidas supports the regulatory role of VDR gene in
bone metabolism as well as different bone metabolism
changes in primigravidas compared to multigravidas.
Simultaneous bone biochemistry in our previous study
indicated that bone turnover is subject to change during
pregnancy. These pregnancy associated changes have
also been demonstrated by others w6x. According to our
previous study, in which we could also demonstrate that
serum osteocalcin reflects bone density by differentiating
fast from slow bone losers, primigravidas with the BB
genotype of the present study are also associated with
higher bone mass losing. In fact, osteocalcin is related
to the current bone mass and provides information about
future bone loss and fracture risk, as a five-year follow-
up study in premenopausal Swedish women has recently
shown w12x. In addition, it could be shown that the effect
of the calcitriol-stimulated osteocalcin secretion in
human osteoblasts was doubled in the bb genotype
compared with the BB genotype w16x. However, the
association between VDR gene BsmI polymorphism and
BMD remains controversial. Gender, age (children vs.
adolescents vs. premenopausal vs. postmenopausal
women), race and ethnicity are the most important influ-
encing factors which could be accounted for the great
diversity between numerous studies w1, 3, 7, 11, 13, 17x.
Moreover, we failed to detect the influence of parity
confirming by several studies which showed similar or
higher BMD in women with many children than in nulli-
parous controls w9x.
In conclusion, only primigravidas show in the first tri-
mester a relation between the bone formation parameter
serum osteocalcin and the VDR genotype BB which is
known to indicate a higher risk of fractures. For further
clinical applications, serum osteocalcin and VDR geno-
type should be tested on a cohort of primigravidas
including measurements of bone density in pregnancy as
well as before and after menopause.
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